Situation and future developments

MEDICEL MeetingMALTA 08.09.11

• Development of disposable microchip for screening of coeliac disease in a portable/hand-held device carrying out multi-analyte tests

• Simultaneous detection of coeliac disease associated autoantibodies (DPG and tissue transglutaminase) and HLA-DQ2 and DQ8 genes.

• The device will have embedded communication abilities for result storage and easy follow-up, management and monitoring of the patient’s response to withdrawal of gluten from the diet.

MEDICEL 2Malta 2011

• Serology– Total IgA, DPG IgG and tTG IgA

• common dilution factor 1:100

• HLA Typing– Alleles

• DQA1*0501 / DQA1*0505

• DQB1*0201 / 0202

• DQB1*0302

– Genotypes• DQ2, DQ8

MEDICEL 3Malta 2011

MEDICEL 4Malta 2011

MEDICEL 5Malta 2011

MEDICEL 6Malta 2011

MEDICEL 7Malta 2011

MEDICEL 8Malta 2011

MEDICEL 9Malta 2011

MEDICEL 10Malta 2011

MEDICEL 11Malta 2011

MEDICEL 12Malta 2011

MEDICEL 13Malta 2011

Hospital Information System

Hospital Information System

Physician’s office

Physician’s office CDMEDICS

InstrumentCDMEDICS Instrument

Demographics Requests/ Replies

Patient / Test information

Patient’s data

• Prototypes of instrumentation: available and tested

• Serology: reagents and prototypes tested

• HLA: reagents and prototypes tested.

MEDICEL 14Malta 2011

• End of the project: June 2012• Instrumentation: final prototype and product line defined• Serology: final reagents within Jan 2012• HLA: final reagents within Jan 2012

• Industrial production: 2013

MEDICEL 15Malta 2011

• Population based screening, and/or screening of high-risk groups and based on the data regarding HLA status, design individually tailored dietary options.

• Monitoring for adherence to the appropriate gluten-free diet either at their GP’s office, or from their own home, with data being communicated directly to their electronic medical record.

• Neonatal screening in risk groups to identify newborns who may develop coeliac disease.

16MEDICEL Malta 2011